Nelly Cherciu

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial

Salomon M. Stemmer, Nebojša Manojlović, Mihai Vasile Marinca et al. · Cancers · 2021 · 48 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A₃ adenosine receptor agonist (A₃AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC).

Salomon M. Stemmer, Nebojša Manojlović, Mihai Vasile Marinca et al. · Journal of Clinical Oncology · 2019 · 11 citations

Medicine, Oncology, Pharmacology +13